Medical device maker AtriCure (NASDAQ:ATRC) is looking to obtain regulatory clearance to use its AtriClip heart device on stroke patients. The Cincinnati-area company is planning next year to begin a ...

AtriCure, Inc. ATRC recently announced the treatment of the first patient with the AtriClip FLEX-Mini device. The device recently received the FDA 510(k) clearance. The AtriClip FLEX-Mini, the ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has ...

AtriCure Inc. (NASDAQ: ATRC) has received regulatory clearance to begin U.S. sales of its AtriClip device, which protects against blood clots during certain heart procedures. The news sent AtriCure’s ...

MASON, Ohio, April 10, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug ...

CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio.

Cleveland, OH - The AtriClip Gillinov-Cosgrove Left Atrial Appendage (LAA) Exclusion system (AtriCure, West Chester, OH) has been approved by the US FDA for occlusion of the LAA, under direct ...